FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020754927> ?p ?o ?g. }

• W2020754927 endingPage "146" @default.
• W2020754927 startingPage "135" @default.
• W2020754927 abstract "Hypercholesterolaemia and hypertension are two major risk factors for atherosclerosis. Each contributes to the progression of plaque, which can eventually occlude arteries leading to myocardial infarction (MI), stroke and peripheral vascular damage. Both elevated blood pressure and high plasma cholesterol can now be controlled with anti-hypertensives and medicines such as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, but no treatments are available that act specifically to reduce or reverse the progression of plaque. Calcium entry blockers (CEBs) are potent anti-hypertensives. However, the rationale for the use of a CEB to interfere with the mechanisms of plaque formation is also strong. It can be hypothesised that CEBs should potentially be able to reduce cholesterol deposition, cellular proliferation and migration and increased cellular matrix, since all of these processes involve calcium. However, CEBs are a heterogeneous class, differing in terms of structure, potency, vascular selectivity and duration of action. In addition, some possess additional properties such as anti-oxidant activity. The newer, third generation dihydropyridines, such as lacidipine, which combine potent CEB activity with long duration of action and anti-oxidant activity, offer the best hope of demonstrating anti-atherosclerotic effects in man. Animal data have confirmed that CEBs are able to reduce plaque progression, though to differing extents. Few so far have been assessed in man. Of those tested, results have not been encouraging. However, the ongoing trials with longer-acting compounds, such as lacidipine (ELSA), are of longer duration and are using B-mode ultrasonography monitoring to afford more precise measurements of atherosclerotic plaque progression. Thus, more consistent daily cover by the CEB should be expected, and the longer monitoring period and the more sensitive measurement should afford an improved chance of demonstrating clinical efficacy." @default.
• W2020754927 created "2016-06-24" @default.
• W2020754927 creator A5020765326 @default.
• W2020754927 creator A5084788721 @default.
• W2020754927 date "1998-06-01" @default.
• W2020754927 modified "2023-09-25" @default.
• W2020754927 title "Calcium antagonists as anti-atherosclerotic agents" @default.
• W2020754927 cites W1587635418 @default.
• W2020754927 cites W1745781907 @default.
• W2020754927 cites W1965408926 @default.
• W2020754927 cites W1971670864 @default.
• W2020754927 cites W1980089653 @default.
• W2020754927 cites W2022023024 @default.
• W2020754927 cites W2038830316 @default.
• W2020754927 cites W2052364512 @default.
• W2020754927 cites W2056101585 @default.
• W2020754927 cites W2056412912 @default.
• W2020754927 cites W2087204275 @default.
• W2020754927 cites W2088799496 @default.
• W2020754927 cites W2089431073 @default.
• W2020754927 cites W2091507377 @default.
• W2020754927 cites W2106073810 @default.
• W2020754927 cites W2117518346 @default.
• W2020754927 cites W2137570167 @default.
• W2020754927 cites W2144561171 @default.
• W2020754927 cites W2157648986 @default.
• W2020754927 cites W2169839369 @default.
• W2020754927 cites W4248108934 @default.
• W2020754927 cites W57789539 @default.
• W2020754927 doi "https://doi.org/10.1517/14728214.3.1.135" @default.
• W2020754927 hasPublicationYear "1998" @default.
• W2020754927 type Work @default.
• W2020754927 sameAs 2020754927 @default.
• W2020754927 citedByCount "2" @default.
• W2020754927 crossrefType "journal-article" @default.
• W2020754927 hasAuthorship W2020754927A5020765326 @default.
• W2020754927 hasAuthorship W2020754927A5084788721 @default.
• W2020754927 hasConcept C126322002 @default.
• W2020754927 hasConcept C127413603 @default.
• W2020754927 hasConcept C134018914 @default.
• W2020754927 hasConcept C164705383 @default.
• W2020754927 hasConcept C170493617 @default.
• W2020754927 hasConcept C2776885963 @default.
• W2020754927 hasConcept C2778163477 @default.
• W2020754927 hasConcept C2779318932 @default.
• W2020754927 hasConcept C2779572014 @default.
• W2020754927 hasConcept C2780645631 @default.
• W2020754927 hasConcept C500558357 @default.
• W2020754927 hasConcept C519063684 @default.
• W2020754927 hasConcept C71924100 @default.
• W2020754927 hasConcept C78519656 @default.
• W2020754927 hasConcept C84393581 @default.
• W2020754927 hasConcept C98274493 @default.
• W2020754927 hasConceptScore W2020754927C126322002 @default.
• W2020754927 hasConceptScore W2020754927C127413603 @default.
• W2020754927 hasConceptScore W2020754927C134018914 @default.
• W2020754927 hasConceptScore W2020754927C164705383 @default.
• W2020754927 hasConceptScore W2020754927C170493617 @default.
• W2020754927 hasConceptScore W2020754927C2776885963 @default.
• W2020754927 hasConceptScore W2020754927C2778163477 @default.
• W2020754927 hasConceptScore W2020754927C2779318932 @default.
• W2020754927 hasConceptScore W2020754927C2779572014 @default.
• W2020754927 hasConceptScore W2020754927C2780645631 @default.
• W2020754927 hasConceptScore W2020754927C500558357 @default.
• W2020754927 hasConceptScore W2020754927C519063684 @default.
• W2020754927 hasConceptScore W2020754927C71924100 @default.
• W2020754927 hasConceptScore W2020754927C78519656 @default.
• W2020754927 hasConceptScore W2020754927C84393581 @default.
• W2020754927 hasConceptScore W2020754927C98274493 @default.
• W2020754927 hasIssue "1" @default.
• W2020754927 hasLocation W20207549271 @default.
• W2020754927 hasOpenAccess W2020754927 @default.
• W2020754927 hasPrimaryLocation W20207549271 @default.
• W2020754927 hasRelatedWork W1966234050 @default.
• W2020754927 hasRelatedWork W1974382241 @default.
• W2020754927 hasRelatedWork W2003842308 @default.
• W2020754927 hasRelatedWork W2025590009 @default.
• W2020754927 hasRelatedWork W2032958076 @default.
• W2020754927 hasRelatedWork W2049397185 @default.
• W2020754927 hasRelatedWork W2064236298 @default.
• W2020754927 hasRelatedWork W2095093072 @default.
• W2020754927 hasRelatedWork W2171089442 @default.
• W2020754927 hasRelatedWork W2399063111 @default.
• W2020754927 hasVolume "3" @default.
• W2020754927 isParatext "false" @default.
• W2020754927 isRetracted "false" @default.
• W2020754927 magId "2020754927" @default.
• W2020754927 workType "article" @default.